Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Compliance with Good Manufacturing Practice in the Assessment of Immunomodulation Potential of Clinical Grade Multipotent Mesenchymal Stromal Cells Derived from Wharton's Jelly.

Grau-Vorster M, Rodríguez L, Del Mazo-Barbara A, Mirabel C, Blanco M, Codinach M, Gómez SG, Querol S, García-López J, Vives J.

Cells. 2019 May 21;8(5). pii: E484. doi: 10.3390/cells8050484.

PMID:
31117301
2.

Adapting Cord Blood Collection and Banking Standard Operating Procedures for HLA-Homozygous Induced Pluripotent Stem Cells Production and Banking for Clinical Application.

Alvarez-Palomo B, Vives J, Casaroli-Marano RPP, G Gomez SG, Rodriguez Gómez L, Edel MJ, Querol Giner S.

J Clin Med. 2019 Apr 8;8(4). pii: E476. doi: 10.3390/jcm8040476. Review.

3.

Extracellular vesicles: Squeezing every drop of regenerative potential of umbilical cord blood.

Roura S, Vives J.

Metabolism. 2019 Jun;95:102-104. doi: 10.1016/j.metabol.2019.02.006. Epub 2019 Mar 1.

PMID:
30831143
4.

Levels of IL-17F and IL-33 correlate with HLA-DR activation in clinical-grade human bone marrow-derived multipotent mesenchymal stromal cell expansion cultures.

Grau-Vorster M, Rodríguez L, Torrents-Zapata S, Vivas D, Codinach M, Blanco M, Oliver-Vila I, García-López J, Vives J.

Cytotherapy. 2019 Jan;21(1):32-40. doi: 10.1016/j.jcyt.2018.09.009. Epub 2018 Nov 15.

PMID:
30447901
5.

Stability enhancement of clinical grade multipotent mesenchymal stromal cell-based products.

Mirabel C, Puente-Massaguer E, Del Mazo-Barbara A, Reyes B, Morton P, Gòdia F, Vives J.

J Transl Med. 2018 Oct 24;16(1):291. doi: 10.1186/s12967-018-1659-4.

6.

Derivation of Multipotent Mesenchymal Stromal Cells from Ovine Bone Marrow.

Vivas D, Caminal M, Oliver-Vila I, Vives J.

Curr Protoc Stem Cell Biol. 2018 Feb 28;44:2B.9.1-2B.9.22. doi: 10.1002/cpsc.43.

PMID:
29512111
7.

Optimisation of a potency assay for the assessment of immunomodulative potential of clinical grade multipotent mesenchymal stromal cells.

Oliver-Vila I, Ramírez-Moncayo C, Grau-Vorster M, Marín-Gallén S, Caminal M, Vives J.

Cytotechnology. 2018 Feb;70(1):31-44. doi: 10.1007/s10616-017-0186-0. Epub 2018 Jan 10.

8.

Toward the clinical use of circulating biomarkers predictive of bone union.

Chaverri D, Vives J.

Biomark Med. 2017 Dec;11(12):1125-1133. doi: 10.2217/bmm-2017-0180. Epub 2017 Nov 28. Review.

PMID:
29182015
9.

Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario?

Roura S, Gálvez-Montón C, Mirabel C, Vives J, Bayes-Genis A.

Stem Cell Res Ther. 2017 Oct 27;8(1):238. doi: 10.1186/s13287-017-0695-y. Review.

10.

Assessment of biodistribution using mesenchymal stromal cells: Algorithm for study design and challenges in detection methodologies.

Reyes B, Coca MI, Codinach M, López-Lucas MD, Del Mazo-Barbara A, Caminal M, Oliver-Vila I, Cabañas V, Lope-Piedrafita S, García-López J, Moraleda JM, Fontecha CG, Vives J.

Cytotherapy. 2017 Sep;19(9):1060-1069. doi: 10.1016/j.jcyt.2017.06.004. Epub 2017 Jul 19.

PMID:
28734679
11.

A reproducible method for the isolation and expansion of ovine mesenchymal stromal cells from bone marrow for use in regenerative medicine preclinical studies.

Caminal M, Vélez R, Rabanal RM, Vivas D, Batlle-Morera L, Aguirre M, Barquinero J, García J, Vives J.

J Tissue Eng Regen Med. 2017 Dec;11(12):3408-3416. doi: 10.1002/term.2254. Epub 2016 Nov 18.

PMID:
27860364
12.

Clinical-scale expansion of CD34+ cord blood cells amplifies committed progenitors and rapid scid repopulation cells.

Casamayor-Genescà A, Pla A, Oliver-Vila I, Pujals-Fonts N, Marín-Gallén S, Caminal M, Pujol-Autonell I, Carrascal J, Vives-Pi M, Garcia J, Vives J.

N Biotechnol. 2017 Mar 25;35:19-29. doi: 10.1016/j.nbt.2016.10.011. Epub 2016 Oct 31.

PMID:
27810336
13.

Clinical translation of a mesenchymal stromal cell-based therapy developed in a large animal model and two case studies of the treatment of atrophic pseudoarthrosis.

Prat S, Gallardo-Villares S, Vives M, Carreño A, Caminal M, Oliver-Vila I, Chaverri D, Blanco M, Codinach M, Huguet P, Ramírez J, Pinto JA, Aguirre M, Coll R, Garcia-López J, Granell-Escobar F, Vives J.

J Tissue Eng Regen Med. 2018 Jan;12(1):e532-e540. doi: 10.1002/term.2323. Epub 2017 Jun 1.

PMID:
27684058
14.

Qualification of computerized monitoring systems in a cell therapy facility compliant with the good manufacturing practices.

Del Mazo-Barbara A, Mirabel C, Nieto V, Reyes B, García-López J, Oliver-Vila I, Vives J.

Regen Med. 2016 Sep;11(6):521-8. doi: 10.2217/rme-2016-0066. Epub 2016 Aug 11.

PMID:
27513321
15.

Design and validation of a consistent and reproducible manufacture process for the production of clinical-grade bone marrow-derived multipotent mesenchymal stromal cells.

Codinach M, Blanco M, Ortega I, Lloret M, Reales L, Coca MI, Torrents S, Doral M, Oliver-Vila I, Requena-Montero M, Vives J, Garcia-López J.

Cytotherapy. 2016 Sep;18(9):1197-208. doi: 10.1016/j.jcyt.2016.05.012. Epub 2016 Jul 14.

PMID:
27424149
16.

Streamlining the qualification of computerized systems in GxP-compliant academic cell therapy facilities.

Del Mazo-Barbara A, Nieto V, Mirabel C, Reyes B, García-López J, Oliver-Vila I, Vives J.

Cytotherapy. 2016 Sep;18(9):1237-9. doi: 10.1016/j.jcyt.2016.06.003. Epub 2016 Jul 12. No abstract available.

PMID:
27421738
17.

Final results of a phase I-II trial using ex vivo expanded autologous Mesenchymal Stromal Cells for the treatment of osteoarthritis of the knee confirming safety and suggesting cartilage regeneration.

Soler R, Orozco L, Munar A, Huguet M, López R, Vives J, Coll R, Codinach M, Garcia-Lopez J.

Knee. 2016 Aug;23(4):647-54. doi: 10.1016/j.knee.2015.08.013. Epub 2016 Jan 11.

PMID:
26783191
18.

Evaluation of a cell-banking strategy for the production of clinical grade mesenchymal stromal cells from Wharton's jelly.

Oliver-Vila I, Coca MI, Grau-Vorster M, Pujals-Fonts N, Caminal M, Casamayor-Genescà A, Ortega I, Reales L, Pla A, Blanco M, García J, Vives J.

Cytotherapy. 2016 Jan;18(1):25-35. doi: 10.1016/j.jcyt.2015.10.001. Epub 2015 Nov 6.

PMID:
26549383
19.

BHRF1 exerts an antiapoptotic effect and cell cycle arrest via Bcl-2 in murine hybridomas.

Milián E, Prats E, Cairó JJ, Gòdia F, Vives J.

J Biotechnol. 2015 Sep 10;209:58-67. doi: 10.1016/j.jbiotec.2015.06.379. Epub 2015 Jun 7.

PMID:
26057602
20.

Quality compliance in the shift from cell transplantation to cell therapy in non-pharma environments.

Vives J, Oliver-Vila I, Pla A.

Cytotherapy. 2015 Aug;17(8):1009-14. doi: 10.1016/j.jcyt.2015.02.002. Epub 2015 Mar 10. Review.

PMID:
25769789

Supplemental Content

Loading ...
Support Center